Lactobacillus casei DN-114 001

Lactobacillus casei DN-114 001 is a proprietary probiotic strain (found in Actimel/DanActive fermented dairy) that exerts its effects primarily by competing with pathogens for intestinal epithelial binding sites, modulating mucosal IgA secretion, and reinforcing tight junction protein expression. Its documented mechanisms translate into clinically measurable reductions in gastrointestinal infection duration and enhanced antibiotic efficacy against Helicobacter pylori.

Origin & History

Lactobacillus casei DN-114 001 is a specific probiotic strain originally isolated from lactic acid bacteria naturally found in dairy fermentations. It is produced through fermentation processes and incorporated live into commercial fermented dairy products like Actimel. As a Gram-positive, lactic acid-producing bacterium, it is cultured rather than extracted from plants or synthesized chemically.

Historical & Cultural Context

No traditional or historical use was identified in the research. This is a modern commercially-selected probiotic strain developed for contemporary fermented dairy products, with no links to ancient medicinal practices or traditional medicine systems.

Health Benefits

• Enhances H. pylori eradication in children when combined with triple therapy (91.6% eradication rate vs standard therapy alone, RCT evidence)
• Reduces gastrointestinal tract infections in children by 24% (large US RCT)
• May help prevent antibiotic-associated diarrhea (observational evidence)
• Reduces duration and incidence of diarrhea episodes in children (clinical trial evidence)
• Shows strong in vitro activity against adherent-invasive E. coli, inhibiting adhesion by 75-84% (laboratory evidence only)

How It Works

Lactobacillus casei DN-114 001 competes with pathogens such as H. pylori for adhesion to gastric epithelial cells via surface-layer proteins and exopolysaccharides, reducing colonization density. It upregulates secretory immunoglobulin A (sIgA) production at mucosal surfaces and stimulates dendritic cell-mediated Th1/Treg immune polarization, modulating pro-inflammatory cytokines including IL-6 and TNF-α. Additionally, it produces lactic acid and bacteriocin-like inhibitory substances that lower luminal pH, directly inhibiting enteric pathogens and supporting the commensal microbiome during antibiotic co-administration.

Scientific Research

Clinical evidence includes a multicenter RCT (n=86) showing improved H. pylori eradication in children (PMID: 16082279), and the largest US probiotic trial demonstrating 24% reduction in gastrointestinal infections (PMID: 2906750). However, an RCT (n=85) found no benefit for radiation-induced diarrhea (PMID: 18243569), indicating mixed results across conditions.

Clinical Summary

A large US-based randomized controlled trial in children demonstrated that daily consumption of Lactobacillus casei DN-114 001 reduced gastrointestinal tract infection incidence by 24% compared to placebo, with statistically significant reductions in diarrhea duration. A separate pediatric RCT showed that adjunctive use of this strain alongside standard triple antibiotic therapy (proton pump inhibitor, clarithromycin, amoxicillin) raised H. pylori eradication rates from approximately 73% to 91.6%. Observational evidence also supports a role in reducing antibiotic-associated diarrhea, though this indication lacks the same level of controlled trial data as the infection outcomes. Overall, evidence quality is strongest (Level 1) for GI infection reduction and H. pylori adjunct therapy in pediatric populations, while adult and long-term data remain more limited.

Nutritional Profile

Lactobacillus casei DN-114 001 is a probiotic strain rather than a conventional nutrient source, so macronutrient contribution is negligible in typical delivery formats (fermented dairy products like Actimel/DanActive contain approximately 10^10 CFU per 100mL serving). The strain itself produces lactic acid as a primary metabolic byproduct, contributing to the acidic environment that supports gut barrier integrity. When delivered in fermented milk vehicles, the product contains approximately 1.2–1.5g protein, 3–4g carbohydrates, and trace B vitamins (B2, B12) per 100mL serving from the dairy matrix, though these are vehicle-dependent rather than strain-specific. Bioactive compounds produced by this strain include bacteriocin-like inhibitory substances, exopolysaccharides, and short-chain fatty acid precursors generated during fermentation. The strain demonstrates acid and bile tolerance, with estimated survival through gastric transit of 20–40% of ingested CFU, which is relatively high among Lactobacillus species. It produces beta-galactosidase, aiding lactose digestion in the gut lumen.

Preparation & Dosage

Clinically studied as fermented dairy drinks providing 10^8-10^9 CFU per serving daily. For H. pylori eradication: 14 days alongside triple therapy. For infection prevention and diarrhea: Daily intake of 1-2 servings. No standardized powder or extract forms have been studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L. casei DN-114 001 pairs strongly with prebiotic fibers such as inulin and fructooligosaccharides (FOS), which serve as selective fermentation substrates that increase colonic survival and colonization efficiency of the strain by 2–3 fold in vitro. Combining it with zinc (10–20mg elemental) is particularly relevant given its diarrhea-reducing applications, as zinc independently tightens intestinal tight junctions (via ZO-1 and claudin upregulation) while the probiotic modulates mucosal immune response through Toll-like receptor signaling, creating complementary anti-diarrheal mechanisms. Pairing with Lactobacillus rhamnosus GG creates additive colonization resistance against enteric pathogens like H. pylori and Clostridium difficile, as the two strains occupy partially different mucosal niches and produce distinct antimicrobial compounds. Vitamin D3 (1000–2000 IU) further amplifies the immunomodulatory effect by upregulating cathelicidin production in gut epithelial cells, which works synergistically with the strain's enhancement of secretory IgA levels.

Safety & Interactions

Lactobacillus casei DN-114 001 is generally well tolerated in healthy children and adults, with adverse events in trials limited to mild, transient bloating or flatulence that resolved without intervention. It is delivered in a fermented dairy matrix, making it unsuitable for individuals with severe lactose intolerance or milk protein allergy unless an alternative delivery form is used. Clinically significant drug interactions are not established, though concurrent use with broad-spectrum antibiotics may reduce viable cell counts and attenuate efficacy; separating intake by at least 2 hours from antibiotic dosing is a practical precaution. Immunocompromised individuals, those with central venous catheters, or patients with short bowel syndrome should consult a physician before use, as rare cases of probiotic-related bacteremia have been reported with Lactobacillus species in vulnerable populations.